Resonant Capital Advisors’s Biogen BIIB Stock Holding History

Resonant Capital Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$402K	Sell	1,862 -12	-0.6%	-$2.29K	0.02%	347
2026 Q1	$344K	Buy	1,874 +190	+11%	+$35K	0.02%	353
2025 Q4	$296K	Buy	1,684 +109	+7%	+$17.8K	0.02%	342
2025 Q3	$221K	Buy	+1,575	New	+$213K	0.01%	403
2021 Q4	–	Sell	-3,515	Closed	-$995K	–	205
2021 Q3	$995K	Buy	3,515 +195	+6%	+$63.9K	0.17%	91
2021 Q2	$1.15M	Buy	3,320 +43	+1%	+$13K	0.22%	84
2021 Q1	$917K	Buy	3,277 +117	+4%	+$31.6K	0.19%	87
2020 Q4	$774K	Buy	3,160 +563	+22%	+$145K	0.18%	89
2020 Q3	$737K	Buy	2,597 +1,289	+99%	+$360K	0.21%	82
2020 Q2	$350K	Buy	1,308 +44	+3%	+$13.2K	0.1%	129
2020 Q1	$400K	Buy	+1,264	New	+$384K	0.15%	142

Other funds holding BIIB

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ADEF

Adams Diversified Equity Fund Baltimore, Maryland $3.27B AUM 45.57% 1-Year Est. Return

Resonant Capital Advisors's BIIB Position: Q2 2026 in Review

Resonant Capital Advisors reduced its Biogen (BIIB) stake by 0.64% in Q2 2026, selling an estimated $2.29K and leaving 1,862 shares worth $402K. The position accounts for 0.02% of the portfolio, ranked #347.

Resonant Capital Advisors first reported a position in BIIB in Q1 2020 and has held it in 11 quarters since. The position peaked at $1.15M in Q2 2021. 405 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Resonant Capital Advisors held 1,862 shares of Biogen worth $402K as of Q2 2026.
Resonant Capital Advisors sold 12 Biogen shares in Q2 2026, an estimated $2.29K.
Biogen made up 0.02% of Resonant Capital Advisors's portfolio in Q2 2026, its #347 holding.
Resonant Capital Advisors first reported a position in Biogen in Q1 2020 and has held it in 11 quarters since.
Resonant Capital Advisors's Biogen position peaked at $1.15M in Q2 2021.
405 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Resonant Capital Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.